A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

Table 3 Mortality risk ratios

	All-cause mortality per 1000 patient-years	Risk ratio
Patients without CKD	45.6^a	N/A
Patients with CKD
CKD stages G1 and G2	82.2^a	1.80^a
CKD stage G3	97.2^a	2.13^a
CKD stages G4 and G5 (excluding dialysis and transplantation)	181.6^a	3.98^a
Dialysis	See USRDS^b	6.86^b
Transplantation	See USRDS^b	2.10^b

CKD Chronic kidney disease; ESRD End-stage renal disease, N/A not applicable, USRDS US Renal Data System
^aSource: USRDS [22], Fig. 3.2 based on all Medicare patients with CKD ≥ 66 years of age. Values are from 2015. Risk ratios were calculated
^bSource: USRDS [23], Table 5.5 based on Medicare patients. Values are from 2014 to 2015. Risk ratios were calculated as the average of the mortality risk ratios for patients with ESRD receiving dialysis or transplantation relative to all Medicare. Mortality risk ratios were calculated for males and females, 65–74 years and ≥ 75 years of age

ISSN: 1471-2369